The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

EDN1  -  endothelin 1

Canis lupus familiaris

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of EDN1


High impact information on EDN1


Chemical compound and disease context of EDN1


Biological context of EDN1


Anatomical context of EDN1

  • METHODS AND RESULTS: ET-1 (group 1, n = 5) or sarafotoxin, a specific ET-B receptor agonist (group 3, n = 6) (each at 2 ng/kg per minute), was infused into the left circumflex coronary artery in the anesthetized dog [15].
  • The endothelium possesses the ability to modulate vascular tone by the release of vasodilators and vasoconstrictors, among them endothelium-derived relaxing factor (EDRF) and endothelin (ET) [16].
  • CONCLUSIONS: Blood flow to normal myocardium is increased at moderate plasma elevations of ET-1, whereas collateral blood flow is unchanged [3].
  • Surprisingly, endothelin-induced increases of Ca2+ were not different in smooth muscle of collateral and noncollateral arteries (P > .05) [17].
  • CONCLUSIONS: Cardiac myocytes have a requisite role in constriction of coronary resistance vessels to alpha1-adrenergic stimuli, which may be mediated by endothelin-1 and other unidentified myocyte-derived vasoconstrictors [6].

Associations of EDN1 with chemical compounds

  • We conclude that the hemodynamic and hormonal adaptation after xenon plus remifentanil and isoflurane plus remifentanil anesthesia does not depend on the endothelin system, because it is unaffected by ET(A) receptor inhibition [18].
  • BACKGROUND: Mature coronary collateral arteries are hyperresponsive to vasopressin; in contrast, contractile responses of collaterals to endothelin are attenuated [17].
  • In the present study, we examined the effects of intravenous bosentan, a nonpeptide, competitive endothelin-1 receptor antagonist, on hemodynamics in dogs with chronic heart failure [19].
  • Coronary collateral vessels demonstrate a much greater dependence on prostacyclin production in blunting the vasoconstrictor properties of ET-1 [3].
  • After indomethacin administration, ET-1 (10 ng/min) caused a 120 +/- 23% increase in collateral vascular resistance (P < .05) and abolished the vasodilation that this dose produced in the normal zone [3].

Regulatory relationships of EDN1


Other interactions of EDN1


Analytical, diagnostic and therapeutic context of EDN1


  1. Elevated endothelin-1 expression in dogs with heartworm disease. Uchide, T., Saida, K. J. Vet. Med. Sci. (2005) [Pubmed]
  2. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. Clavell, A.L., Mattingly, M.T., Stevens, T.L., Nir, A., Wright, S., Aarhus, L.L., Heublein, D.M., Burnett, J.C. J. Clin. Invest. (1996) [Pubmed]
  3. Dose-dependent effect of endothelin-1 on blood flow to normal and collateral-dependent myocardium. Traverse, J.H., Judd, D., Bache, R.J. Circulation (1996) [Pubmed]
  4. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Donckier, J., Stoleru, L., Hayashida, W., Van Mechelen, H., Selvais, P., Galanti, L., Clozel, J.P., Ketelslegers, J.M., Pouleur, H. Circulation (1995) [Pubmed]
  5. Integrated cardiac, renal, and endocrine actions of endothelin. Miller, W.L., Redfield, M.M., Burnett, J.C. J. Clin. Invest. (1989) [Pubmed]
  6. Requisite role of cardiac myocytes in coronary alpha1-adrenergic constriction. Tiefenbacher, C.P., DeFily, D.V., Chilian, W.M. Circulation (1998) [Pubmed]
  7. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Donckier, J.E., Massart, P.E., Hodeige, D., Van Mechelen, H., Clozel, J.P., Laloux, O., Ketelslegers, J.M., Charlier, A.A., Heyndrickx, G.R. Circulation (1997) [Pubmed]
  8. Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the canine liver. Kitayama, Y., Yamanaka, N., Kawamura, E., Kuroda, N., Okamoto, E. Hepatology (1997) [Pubmed]
  9. Efficacy of administering an endothelin-receptor antagonist (SB209670) in ameliorating ischemia-reperfusion injury in lung allografts. Shennib, H., Lee, A.G., Kuang, J.Q., Yanagisawa, M., Ohlstein, E.H., Giaid, A. Am. J. Respir. Crit. Care Med. (1998) [Pubmed]
  10. High-fructose feeding elicits insulin resistance, hyperinsulinism, and hypertension in normal mongrel dogs. Martinez, F.J., Rizza, R.A., Romero, J.C. Hypertension (1994) [Pubmed]
  11. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension. Massart, P.E., Hodeige, D.G., Van Mechelen, H., Charlier, A.A., Ketelslegers, J.M., Heyndrickx, G.R., Donckier, J.E. J. Hypertens. (1998) [Pubmed]
  12. Primary structure of cat preproendothelin-2 and cat renal mRNA expression of preproendothelin-1 and preproendothelin-2 in naturally occurring renal failure. Uchide, T., Saida, K. Exp. Biol. Med. (Maywood) (2006) [Pubmed]
  13. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Sudhir, K., MacGregor, J.S., DeMarco, T., De Groot, C.J., Taylor, R.N., Chou, T.M., Yock, P.G., Chatterjee, K. Circulation (1994) [Pubmed]
  14. Increased endothelin in experimental heart failure. Margulies, K.B., Hildebrand, F.L., Lerman, A., Perrella, M.A., Burnett, J.C. Circulation (1990) [Pubmed]
  15. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Cannan, C.R., Burnett, J.C., Brandt, R.R., Lerman, A. Circulation (1995) [Pubmed]
  16. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Lerman, A., Sandok, E.K., Hildebrand, F.L., Burnett, J.C. Circulation (1992) [Pubmed]
  17. Mechanisms of altered contractile responses to vasopressin and endothelin in canine coronary collateral arteries. Rapps, J.A., Jones, A.W., Sturek, M., Magliola, L., Parker, J.L. Circulation (1997) [Pubmed]
  18. Endothelin-a receptor blockade does not debilitate the cardiovascular and hormonal adaptation to xenon or isoflurane anesthesia in dogs. Francis, R.C., Höhne, C., Klein, A., Donaubauer, B., Kaisers, U., Boemke, W. Exp. Biol. Med. (Maywood) (2006) [Pubmed]
  19. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Shimoyama, H., Sabbah, H.N., Borzak, S., Tanimura, M., Shevlyagin, S., Scicli, G., Goldstein, S. Circulation (1996) [Pubmed]
  20. Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells. Jougasaki, M., Larsen, A.M., Cataliotti, A., Christiansen, D.C., Burnett, J.C. Peptides (2002) [Pubmed]
  21. The selective endothelin-A-receptor antagonist LU 135.252 inhibits the direct arrhythmogenic action of endothelin-1. Merkely, B., Szabó, T., Gellér, L., Kiss, O., Horkay, F., Raschack, M., Juhász-Nagy, A. J. Cardiovasc. Pharmacol. (2000) [Pubmed]
  22. Endothelin-1 promotes vascular structural remodeling during the progression of heart failure prevention of vascular remodeling using a specific endothelin-converting enzyme inhibitor. Wang, X., Ohnishi, M., Wada, A., Tsutamoto, T., Sawaki, M., Fujii, M., Matsumoto, T., Yamamoto, T., Kurokawa, K., Yamada, H., Kinoshita, M. Life Sci. (2001) [Pubmed]
  23. Renal actions of endothelin: interaction with prostacyclin. Chou, S.Y., Dahhan, A., Porush, J.G. Am. J. Physiol. (1990) [Pubmed]
  24. Effects of renin-angiotensin system in mediating endothelin-induced renal vasoconstriction: therapeutic implications. Chan, D.P., Clavell, A., Keiser, J., Burnett, J.C. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. (1994) [Pubmed]
  25. Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury. Kawamura, E., Yamanaka, N., Okamoto, E., Tomoda, F., Furukawa, K. Hepatology (1995) [Pubmed]
  26. Effect of endothelin-1 on glomerular hydraulic pressure and renin release in dogs. Lin, H., Sangmal, M., Smith, M.J., Young, D.B. Hypertension (1993) [Pubmed]
  27. Stimulation of the renin-angiotensin system by endothelin subtype A receptor blockade in conscious dogs. Berthold, H., Münter, K., Just, A., Kirchheim, H.R., Ehmke, H. Hypertension (1999) [Pubmed]
  28. Renal protection by a dual ETA/ETB endothelin antagonist, L-754,142, after aortic cross-clamping in the dog. Krause, S.M., Walsh, T.F., Greenlee, W.J., Ranaei, R., Williams, D.L., Kivlighn, S.D. J. Am. Soc. Nephrol. (1997) [Pubmed]
  29. Autonomic modulation of contractions to endothelin-1 in canine coronary arteries. Aarnio, P., McGregor, C.G., Miller, V. Hypertension (1993) [Pubmed]
WikiGenes - Universities